May 1984
Volume 25, Issue 5
Free
Articles  |   May 1984
Suppression of HSV-1 infection in trigeminal ganglion cells. An in vitro model of latency.
Investigative Ophthalmology & Visual Science May 1984, Vol.25, 525-533. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E C Dunkel, M T Green, J P Rosborough; Suppression of HSV-1 infection in trigeminal ganglion cells. An in vitro model of latency.. Invest. Ophthalmol. Vis. Sci. 1984;25(5):525-533.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
This content is PDF only. Please click on the PDF icon to access.
Abstract

The goal of this experiment was to develop an in vitro model of HSV-1 infection and to characterize the virologic parameters associated with such an infection. An in vitro model of HSV-1 infection would offer a defined, efficient, and easily controlled system for studying the mechanisms associated with HSV-1 latency and reactivation. Results indicate that: (1) in the presence of 100 micrograms/ml acyclovir, acute infection is suppressed within 3 days; (2) during suppression, infectious virus was recovered only from whole cell trigeminal ganglion explants (no virus recovery from supernate or homogenized samples); immunofluorescent staining was evident with antiserum to VP175, but not with antiserum to HSV-1 and intranuclear inclusions, but no intact virions were observed in neurons by electron microscopy; (3) 72 hr after desuppression of HSV infected trigeminal ganglion cells infectious HSV-1 was recovered from supernate, homogenized, and whole cell cultures. Immunofluorescent staining was observed with antisera to VP175 and HSV-1; intranuclear inclusions as well as intact virus particles were noted in neurons via electron microscopy.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×